1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 18,500 | 19,100 | 12:24 | |
| 8,450 | 9,800 | 31.03.20 |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 06.01. | Sutro: Leading Cell Free Protein Synthesis Company With Promising Early Data | 5 | Seeking Alpha | ||
| 09.12.20 | Sutro Biopharma prices $126M public offering | 5 | Seeking Alpha | ||
| 09.12.20 | Sutro Biopharma (STRO) Investor Presentation - Slideshow | 1 | Seeking Alpha | ||
| SUTRO BIOPHARMA Aktie jetzt für 0€ handeln | |||||
| 08.12.20 | Why iBio, Sutro And Cantel Medical Are Moving Today | 16 | Benzinga.com | ||
| 08.12.20 | Sutro Biopharma -4.6% after filing to offer 5M shares | 2 | Seeking Alpha | ||
| 07.12.20 | SUTRO BIOPHARMA, INC. - 8-K, Current Report | 2 | SEC Filings | ||
| 07.12.20 | Sutro Biopharma down after STRO-001 data in blood cancer study | 1 | Seeking Alpha | ||
| 05.12.20 | Why Sutro Biopharma Blasted 33% Higher on Friday | 6 | The Motley Fool | ||
| 04.12.20 | Mid-Afternoon Market Update: Dow Surges 200 Points; Sutro Biopharma Shares Spike Higher | 2 | Benzinga.com | ||
| 04.12.20 | Sutro Biopharma: 7 Things for STRO Stock Investors to Know About the Biotech Company | 3 | InvestorPlace | ||
| 04.12.20 | Sutro Biopharma, Merrimack Pharmaceuticals leads healthcare gainers; Precision BioSciences, Cortexyme among major losers | 16 | Seeking Alpha | ||
| 04.12.20 | Sutro's antibody-drug conjugate impresses in hard-to-treat ovarian cancer | 5 | FierceBiotech | ||
| 04.12.20 | The Daily Biotech Pulse: BioCryst's Heredity Angioedema Treatment Clears FDA, Sutro Biopharma Readout, 2 IPOs | 6 | Benzinga.com | ||
| 04.12.20 | Sutro's continued PhI data readouts indicate improving response in ovarian cancer. What's next? | 3 | Endpoints News | ||
| 04.12.20 | FDA Nod For BCRX - Decision In Japan, Europe Next, ENLV Soars On COVID Trial Data, Sutro Biopharma Abuzz | 1.150 | AFX News | NEW BRUNSWICK (dpa-AFX) - Today's Daily Dose brings you news about Johnson & Johnson submitting the first-ever drug for a mutation-specific lung cancer to the FDA, Sutro Biopharma's encouraging... ► Artikel lesen | |
| 04.12.20 | Sutro +23.5% as ovarian cancer drug study offers encouraging interim data | 4 | Seeking Alpha | ||
| 03.12.20 | Why Sutro, Lumos And More Health Care Stocks Are Moving Today | 1 | Benzinga.com | ||
| 01.12.20 | SUTRO BIOPHARMA, INC. - 8-K, Current Report | - | SEC Filings | ||
| 05.11.20 | SUTRO BIOPHARMA, INC. - 8-K, Current Report | 1 | SEC Filings | ||
| 05.11.20 | SUTRO BIOPHARMA, INC. - 10-Q, Quaterly Report | 1 | SEC Filings |
Seite:
1 2 Weiter >>
27 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| OCUGEN | 6,980 | -4,90 % | Ocugen: Mein möglicher Geheimtipp der Woche | Nicht nur bei BioNTech, sondern auch bei Astra Zeneca scheint es Produktions- und Lieferengpässe zu geben. Davon könnte die Ocugen Aktie jetzt profitieren Den vollständigen Artikel lesen ... ► Artikel lesen | |
| CTI BIOPHARMA | 2,650 | +1,53 % | EARNINGS SUMMARY: Details of CTI BioPharma Corp. Q3 Earnings Report | WASHINGTON (dpa-AFX) - Below are the earnings highlights for CTI BioPharma Corp. (CTIC):-Earnings: -$11.26 million in Q3 vs. -$10.05 million in the same period last year.
-EPS: -$0.15 in... ► Artikel lesen | |
| INTELLIA THERAPEUTICS | 51,48 | -1,38 % | Intellia Therapeutics Q4 2020 Earnings Preview | ||
| AMYRIS | 12,550 | +0,08 % | Amyris launches Pipette clean baby care brand in 600 Target retail stores across North America | ||
| ONCONOVA THERAPEUTICS | 1,184 | -6,77 % | Onconova Therapeutics, Inc.: Onconova Therapeutics Regains Compliance with Nasdaq Continued Listing Requirement | ||
| CYTRX | 3,360 | -0,59 % | CytRx Corporation: CytRx Highlights Orphazyme's Submission of European Marketing Authorisation for Arimoclomol to Treat Niemann-Pick Disease Type C | Applauds Orphazyme's Efforts to Pursue Approval in Europe for Arimoclomol in the Treatment of Niemann-Pick Disease Type C Notes That Arimoclomol for Niemann-Pick Disease Type C is Under the FDA's... ► Artikel lesen | |
| SESEN BIO | 2,257 | -3,51 % | Sesen Bio: Vicineum's Priority Review Provides Conviction To Hold Through PDUFA Date | ||
| LEXICON PHARMACEUTICALS | 6,242 | +1,96 % | FDA Expands Approved Use Of Pfizer's Xalkori, LXRX Soars On Sotagliflozin Update, BCYC Hits New High | NEW YORK CITY (dpa-AFX) - Today's Daily Dose brings you news about Lexicon's regulatory update on Sotagliflozin in heart failure; FDA approval of Pfizer's XALKORI in a new indication; Bicycle's... ► Artikel lesen | |
| INFINITY PHARMACEUTICALS | 2,800 | 0,00 % | Piper Sandler initiates Infinity Pharmaceuticals at overweight | ||
| MACROGENICS | 16,900 | +1,20 % | MacroGenics, Inc.: MacroGenics Announces Date of Fourth Quarter and Full Year 2020 Financial Results Conference Call | ||
| APPLIED GENETIC TECHNOLOGIES | 4,460 | -3,88 % | AGTC Sheds Light On Achromatopsia Trials, Eli Lilly, VIR And GSK Team Up, CVM Turns Head As It Awaits Data | LONDON (dpa-AFX) - Today's Daily Dose brings you news about Applied Genetic's Achromatopsia trial results; the deadlock in AstraZeneca vaccine supply in EU; partnership of Lilly, Vir Biotech... ► Artikel lesen | |
| REGENXBIO | 32,690 | -1,09 % | Regenxbio Gene Therapy Shows Treatment Benefit In Wet AMD Study | ||
| KALVISTA PHARMACEUTICALS | 28,200 | +0,71 % | KalVista Pharmaceuticals, Inc.: KalVista Pharmaceuticals Announces Pricing of an Upsized $193.5 Million Public Offering of Common Stock | KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) today announced the pricing of its upsized underwritten public offering of 5,375,000 shares of its common stock at a price to the public of $36.00 per... ► Artikel lesen | |
| ONCTERNAL THERAPEUTICS | 5,950 | +2,59 % | Oncternal Therapeutics to Participate in March Investor Conferences | ||
| MINERVA NEUROSCIENCES | 2,780 | +1,46 % | SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Minerva Neurosciences, Inc. of Class Action Lawsuit and Upcoming Deadline - NERV | NEW YORK, Jan. 31, 2021 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Minerva Neurosciences, Inc. ("Minerva" or the "Company") (NASDAQ: NERV)... ► Artikel lesen |
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und
